A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer

Sarita Prabhakaran; Guang Xing; Ashleigh Hocking; Matthew Hussey; Douglas W Henderson; Sonja Klebe

doi:10.2147/PLMI.S204421

A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer

Sarita Prabhakaran, Guang Xing, Ashleigh Hocking, Matthew Hussey, Douglas W Henderson, Sonja Klebe

Research output: Contribution to journal › Article › peer-review

146 Downloads (Pure)

Abstract

Purpose: Classification of non-small cell lung carcinoma (NSCLC), as adenocarcinoma or squamous cell carcinoma, is important both in the diagnosis and treatment of lung cancer. Use of appropriate markers for this identification is crucial in order to conserve patient tissue for further molecular testing that could guide treatment decisions and have prognostic implications. Patients and methods: We constructed tissue microarrays from archival resections of 200 NSCLC that were previously subtyped based on morphology and immunohistochemistry (IHC) in some cases. We performed IHC with three TTF-1 clones (SP141, SPT24 and 8G7G3/1), Napsin A, p40, p63 and CK5/6 and panels of four or two markers that best help identify adenocarcinoma and squamous cell carcinoma were ascertained. Results: Our results showed that the best four-marker panel utilized TTF-1 (clone SP141), Napsin A, p63 and CK5/6 with a sensitivity of 98.3% and high specificity of 91.7%. The best two-marker panel was TTF-1 (clone SP141) and p63 with 96.5% sensitivity and 85.71% specificity. Conclusion: As there are variations in the performance of different clones of TTF-1 IHC antibodies, the clone chosen can increase the diagnostic value in differentiating adenocarcinoma from squamous cell carcinoma. In the panels analyzed, the survival of cases concordant with the diagnosis had longer survival compared to those that were discordant. The difference was however not statistically significant (p>0.05).

Original language	English
Pages (from-to)	7-15
Number of pages	9
Journal	Pathology and Laboratory Medicine International
Volume	11
DOIs	https://doi.org/10.2147/PLMI.S204421
Publication status	Published - 11 Sept 2019

Bibliographical note

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Keywords

non-small cell lung carcinoma
immunohistochemistry
squamous cell carcinoma
adenocarcinoma

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2147/PLMI.S204421Licence: CC BY-NC

Published versionFinal published version, 747 KBLicence: CC BY-NC

Cite this

@article{1f9988b78a304dc3b652872e59715629,

title = "A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer",

abstract = "Purpose: Classification of non-small cell lung carcinoma (NSCLC), as adenocarcinoma or squamous cell carcinoma, is important both in the diagnosis and treatment of lung cancer. Use of appropriate markers for this identification is crucial in order to conserve patient tissue for further molecular testing that could guide treatment decisions and have prognostic implications. Patients and methods: We constructed tissue microarrays from archival resections of 200 NSCLC that were previously subtyped based on morphology and immunohistochemistry (IHC) in some cases. We performed IHC with three TTF-1 clones (SP141, SPT24 and 8G7G3/1), Napsin A, p40, p63 and CK5/6 and panels of four or two markers that best help identify adenocarcinoma and squamous cell carcinoma were ascertained. Results: Our results showed that the best four-marker panel utilized TTF-1 (clone SP141), Napsin A, p63 and CK5/6 with a sensitivity of 98.3% and high specificity of 91.7%. The best two-marker panel was TTF-1 (clone SP141) and p63 with 96.5% sensitivity and 85.71% specificity. Conclusion: As there are variations in the performance of different clones of TTF-1 IHC antibodies, the clone chosen can increase the diagnostic value in differentiating adenocarcinoma from squamous cell carcinoma. In the panels analyzed, the survival of cases concordant with the diagnosis had longer survival compared to those that were discordant. The difference was however not statistically significant (p>0.05).",

keywords = "non-small cell lung carcinoma, immunohistochemistry, squamous cell carcinoma, adenocarcinoma",

author = "Sarita Prabhakaran and Guang Xing and Ashleigh Hocking and Matthew Hussey and Henderson, {Douglas W} and Sonja Klebe",

note = "This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms. ",

year = "2019",

month = sep,

day = "11",

doi = "10.2147/PLMI.S204421",

language = "English",

volume = "11",

pages = "7--15",

journal = "Pathology and Laboratory Medicine International",

issn = "1179-2698",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer

AU - Prabhakaran, Sarita

AU - Xing, Guang

AU - Hocking, Ashleigh

AU - Hussey, Matthew

AU - Henderson, Douglas W

AU - Klebe, Sonja

N1 - This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

PY - 2019/9/11

Y1 - 2019/9/11

N2 - Purpose: Classification of non-small cell lung carcinoma (NSCLC), as adenocarcinoma or squamous cell carcinoma, is important both in the diagnosis and treatment of lung cancer. Use of appropriate markers for this identification is crucial in order to conserve patient tissue for further molecular testing that could guide treatment decisions and have prognostic implications. Patients and methods: We constructed tissue microarrays from archival resections of 200 NSCLC that were previously subtyped based on morphology and immunohistochemistry (IHC) in some cases. We performed IHC with three TTF-1 clones (SP141, SPT24 and 8G7G3/1), Napsin A, p40, p63 and CK5/6 and panels of four or two markers that best help identify adenocarcinoma and squamous cell carcinoma were ascertained. Results: Our results showed that the best four-marker panel utilized TTF-1 (clone SP141), Napsin A, p63 and CK5/6 with a sensitivity of 98.3% and high specificity of 91.7%. The best two-marker panel was TTF-1 (clone SP141) and p63 with 96.5% sensitivity and 85.71% specificity. Conclusion: As there are variations in the performance of different clones of TTF-1 IHC antibodies, the clone chosen can increase the diagnostic value in differentiating adenocarcinoma from squamous cell carcinoma. In the panels analyzed, the survival of cases concordant with the diagnosis had longer survival compared to those that were discordant. The difference was however not statistically significant (p>0.05).

AB - Purpose: Classification of non-small cell lung carcinoma (NSCLC), as adenocarcinoma or squamous cell carcinoma, is important both in the diagnosis and treatment of lung cancer. Use of appropriate markers for this identification is crucial in order to conserve patient tissue for further molecular testing that could guide treatment decisions and have prognostic implications. Patients and methods: We constructed tissue microarrays from archival resections of 200 NSCLC that were previously subtyped based on morphology and immunohistochemistry (IHC) in some cases. We performed IHC with three TTF-1 clones (SP141, SPT24 and 8G7G3/1), Napsin A, p40, p63 and CK5/6 and panels of four or two markers that best help identify adenocarcinoma and squamous cell carcinoma were ascertained. Results: Our results showed that the best four-marker panel utilized TTF-1 (clone SP141), Napsin A, p63 and CK5/6 with a sensitivity of 98.3% and high specificity of 91.7%. The best two-marker panel was TTF-1 (clone SP141) and p63 with 96.5% sensitivity and 85.71% specificity. Conclusion: As there are variations in the performance of different clones of TTF-1 IHC antibodies, the clone chosen can increase the diagnostic value in differentiating adenocarcinoma from squamous cell carcinoma. In the panels analyzed, the survival of cases concordant with the diagnosis had longer survival compared to those that were discordant. The difference was however not statistically significant (p>0.05).

KW - non-small cell lung carcinoma

KW - immunohistochemistry

KW - squamous cell carcinoma

KW - adenocarcinoma

U2 - 10.2147/PLMI.S204421

DO - 10.2147/PLMI.S204421

M3 - Article

SN - 1179-2698

VL - 11

SP - 7

EP - 15

JO - Pathology and Laboratory Medicine International

JF - Pathology and Laboratory Medicine International

ER -

A comparison of diagnostic panels in the immunohistochemical analysis of lung cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this